^
    2ms
    A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Betta Pharmaceuticals Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    tibremciclib (BPI-16350)
    5ms
    A Single-center, Open-label, Fixed-sequence, Drug-Drug Interaction Study of BPI-16350 co-administered with Rifampin or Itraconazole in Healthy Volunteers (ChiCTR2400090190)
    P1, N=36, Completed, Beijing Friendship Hospital ,Capital Medical University; Beijing Friendship Hospital ,Capital Medical University
    New P1 trial
    |
    itraconazole • tibremciclib (BPI-16350) • rifampicin
    over1year
    A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=274, Active, not recruiting, Betta Pharmaceuticals Co., Ltd. | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    fulvestrant • tibremciclib (BPI-16350)
    almost3years
    A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=267, Not yet recruiting, Betta Pharmaceuticals Co., Ltd.
    New P3 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    fulvestrant • tibremciclib (BPI-16350)